Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Assiut Univ. EGFR compound 8d
- Development stage
- Unknown
- Lead developer
- Assiut University
01
Overview
Assiut Univ. EGFR compound 8d: sourced facts only. name: "Additionally, compounds 7d and 8d showed inhibitory activity against EGFRWT (0.084, 0.068 μM, respectively), EGFRT790M (0.287 ± 0.01, 0.154 ± 0.004 μM, respectively), and VEGFR-2 (0.075, 0.071 μM, respectively)." [PMID:42715623]; target: "Additionally, compounds 7d and 8d showed inhibitory activity against EGFRWT (0.084, 0.068 μM, respectively), EGFRT790M (0.287 ± 0.01, 0.154 ± 0.004 μM, respectively), and VEGFR-2 (0.075, 0.071 μM, respectively)." [PMID:42715623]; developer: "Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Badr University in Assiut (BUA), Assiut 71511, Egypt. Electronic address: [email protected]." [PMID:42715623]
02
Targets
Beyond the preview
Go deeper on Assiut Univ. EGFR compound 8d.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Assiut Univ. EGFR compound 8d.